Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
17.2
Year-on-year change in revenue (%)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
Interim period (second quarter)2023年6月1日〜2023年11月30日ConsolidatedJapanese GAAPNet Sales2,342¥ millionYear on year +17.2%Progress 46.8%
Operating profit169¥ millionYear on year -4.5%Progress 44.5%
Ordinary income194¥ millionYear on year -5.4%Progress 53.9%
Net income attributable to owners of the parent115¥ millionYear on year -0.4%Progress 53.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥12.80
Financial position at period-end
Total assets3,568¥ million
of which net assets 2,029 ¥ millionEquity ratio 56.4%vs. prior year-end +1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-130,900
Investment-14,267
Financials+14,100
Net change-131,067
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥1,394,325 thousand
Segment revenueMedia and Platform Business ¥562,129 thousand (YoY +12.6%), Healthcare Institution Management Support Business ¥1,708,274 thousand (YoY +20.8%), Medical B2B Business ¥69,829 thousand (YoY -15.8%), Other ¥1,812 thousand
Segment profitMedia and Platform Business ¥314,565 thousand (YoY +5.9%), Healthcare Institution Management Support Business ¥68,226 thousand (YoY +32.5%), Medical B2B Business ¥7,154 thousand (YoY -71.9%), Other ¥1,812 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥5,000 million (YoY +11.1%)
Operating profit¥380 million (YoY +0.3%)
Ordinary income¥360 million (YoY -16.7%)
Net income¥214 million (YoY +84.6%)
Annual Dividend Forecast¥2.5 → ¥3（+20.0%）
Factors Behind Changes in Business Performance
事業を拡大したことにより売上高が増加した一方、事業拡大のための人材採用を強化したことにより人件費が増加し、営業利益が減少した。
Disclosure regarding the going concern assumption
No applicable matters ("There are no applicable matters")
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies (company name: —) / Excluded 0 companies (company name: —)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥2,552 thousand / Extraordinary loss Impairment Loss on Investment Securities ¥4,269 thousand
Depreciation and amortization¥8,951 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and securities analysts)
Issued Shares at Period-End10,773,000
Treasury Shares at Period-End1,727,730
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2023年6月1日〜2023年11月30日 |
| Net Sales | ¥2,342 million (YoY +17.2%) |
| Operating profit | ¥169 million (YoY -4.5%) |
| Ordinary income | ¥194 million (YoY -5.4%) |
| Profit attributable to owners of the parent | ¥115 million (YoY -0.4%) |
| Net income per share | ¥12.80 |
| Equity ratio | End of the current fiscal period 56.4 / End of previous period 55.3 |
| Total assets | ¥3,568 million |
| Net assets | ¥2,029 million |
| Cash flows from operating activities | ¥-130,900 thousand |
| Cash flows from investing activities | ¥-14,267 thousand |
| Cash flows from financing activities | ¥14,100 thousand |
| Cash and cash equivalents at end of period | ¥1,394,325 thousand |
| Full-year earnings forecast | Net Sales ¥5,000 million (YoY +11.1%) / Operating profit ¥380 million (YoY +0.3%) / Ordinary income ¥360 million (YoY -16.7%) / Net income ¥214 million (YoY +84.6%) |
| Annual Dividend Forecast | ¥2.5 → ¥3（+20.0%） |
| Segment revenue | Media and Platform Business ¥562,129 thousand (YoY +12.6%), Healthcare Institution Management Support Business ¥1,708,274 thousand (YoY +20.8%), Medical B2B Business ¥69,829 thousand (YoY -15.8%), Other ¥1,812 thousand |
| Segment profit | Media and Platform Business ¥314,565 thousand (YoY +5.9%), Healthcare Institution Management Support Business ¥68,226 thousand (YoY +32.5%), Medical B2B Business ¥7,154 thousand (YoY -71.9%), Other ¥1,812 thousand |
| Depreciation and amortization | ¥8,951 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,552 thousand / Extraordinary loss Impairment Loss on Investment Securities ¥4,269 thousand |
| Disclosure regarding the going concern assumption | No applicable matters ("There are no applicable matters") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies (company name: —) / Excluded 0 companies (company name: —) |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 10,773,000 |
| Treasury Shares at Period-End | 1,727,730 |
| Factors Behind Changes in Business Performance | 事業を拡大したことにより売上高が増加した一方、事業拡大のための人材採用を強化したことにより人件費が増加し、営業利益が減少した。 |
Items this document does not state (8)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogImpairment lossMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.事業を拡大したことにより売上高は増加した一方、事業拡大のための人材採用を強化したことにより人件費が増加し、営業利益は減少した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.